期刊文献+

慢性乙型肝炎患者核苷(酸)类似物停药的研究进展 被引量:7

Research advances in withdrawal of nucleos(t)ide analogues in chronic hepatitis B patients
原文传递
导出
摘要 核苷(酸)类似物治疗慢性乙型肝炎的停药问题一直是学者及患者关注的临床问题。在临床实践中,很多研究结果显示核苷(酸)类似物停药复发率较高。患者年龄、基线HBVDNA载量、药物巩固治疗时间以及HBsAg水平是核昔(酸)类似物停药复发的相关因素。此外,有关核昔(酸)类似物停药后的安全性及复发后再治疗的应答问题也有很多研究。现就以上几个方面的研究进展进行综述。 Withdrawal of nucleos(t)ide analogues in chronic hepatitis B patients has always been a clinical problem for scholars and patients. Many studies showed that the withdrawal of nucleos(t)ide analogues often leads to a high recurrence rate in clinical practice. The factors such as age, baseline HBV DNA load, time of drug consolidation therapy, and HBsAg level are associated with recurrence after withdrawal of nucleos(t)ide analogues. In addition~ there are many studies on safety after withdrawal of nucleos(t)ide analogues and response to retreatment after recurrence. This article reviews the research advances in the aspects mentioned above.
作者 胡娜 尤红
出处 《中华肝脏病杂志》 CAS CSCD 北大核心 2016年第9期704-707,共4页 Chinese Journal of Hepatology
关键词 肝炎 乙型 慢性 核苷(酸)类似物 停药 Hepatitis B, chronic Nucleos(t)ide analogues Off-treatment
  • 相关文献

参考文献3

二级参考文献22

  • 1Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association.肝衰竭诊疗指南[J].中华肝脏病杂志,2006,14(9):643-646. 被引量:830
  • 2Wiens A, Lenzi L, Venson R, et al. Comparative efficacy of oral nu- cleoside or nucleotide analog monotherapy used in chronic hepatitis B: a mixed-treatment comparison recta-analysis [ J ]. Pharmacotherapy, 2013, 33(2) : 144 -151.
  • 3Petersen J, Buti M. Considerations for the long-term treatment of chro- nic hepatitis B with nucleos(t) ide analogs[ J]. Expert Rev Gastroen- terol Hepatol, 2012, 6(6) : 683 -694.
  • 4Levrero M, Pollicino T, Petersen J, et al. Control of eecDNA function in hepatitis B virus infection[J]. J Hepatol, 2009, 51(3): 581 -592.
  • 5Honkoop P, de-Man R A, Niesters H G, et al. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine thera- py[J]. Hepatology, 2000, 32(3): 635 -639.
  • 6Borroto-Esoda K, Miller M D, Arterburn S. Meta-analysis across ade-fovir clinical trials demonstrates the absence of novel adefovir-associated mutations and confirms the role of the rtA181V and rtN236T mutations in HBV polymerase in association with virologic failure [ J ]. Hepatolo- gy, 2006, 44(4) : 552A.
  • 7Tenney D J, Langley D R, Oliver A J, et al. Hepatitis B virus resist- ance to entecavir involves novel changes in the viral polymerase [ J ]. Hepatology, 2004, 40(4) : 245A.
  • 8Locarnini S. Primary resistance, muhidrug resistance, and cross-resist- ance pathways in HBV as a consequence of treatment failure[ J ]. Hep- atol Int, 2008, 2(2) : 147 -151.
  • 9Marinos G, Naoumov N V, Williams R. Impact of complete inhibition of viral replication on the cellular immune response in chronic hepati- tis B virus infection[J]. Hepatology, 1996, 24(5) : 991 -995.
  • 10European Association for the Study of the Liver.EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection[J]. Journal of Hepatology . 2012 (1)

共引文献25

同被引文献32

引证文献7

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部